worldUpdated: Oct 18, 2020, 19:18 ISTResearchers in China have confirmed that BBIBP-CorV, a vaccine currently under human trial observation, has safely triggered the expected antibody immune responses. The combined early and mid-stage trials for the vaccine happened between April 29 and July 30 this year. Beijing Institute of Biological Products, a subsidiary of China National Biotec Group (CNBG), is currently developing the vaccine. It is one of ten potential vaccine candidates that have entered the Phase III trials around the world. Participants aged 60 and above were also found to be slower in developing antibody responses and multiplying them, than people of younger age groups.

Source: Hindustan Times October 18, 2020 10:28 UTC